Programmed death ligand-1 expression in non-small cell lung cancerVamsidhar Velcheti, David L. Rimm, Kurt A. Schalper et al.|Laboratory Investigation|2013Cited by 753
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Mark M. Awad, Xinan Wang et al.|JAMA Oncology|2022Cited by 383
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)Daniel Carvajal‐Hausdorf, Kurt A. Schalper|Journal for ImmunoTherapy of Cancer|2019Cited by 195
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockersScott Gettinger, Kurt A. Schalper|Nature Communications|2018Cited by 189
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerArvind Ravi, Justin F. Gainor, Jaegil Kim et al.|Nature Genetics|2023Cited by 185